Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study

M. Roldo, E. Barbu, J.F. Brown, D.W. Laight, John Smart, J. Tsibouklis

Research output: Contribution to journalArticle

Abstract

Radiolabeled congeners of a series of azopolymers have been synthesized and characterized. The in vivo (rat) gastrointestinal transit profile of millimeter-sized particles of these azopolymers has been determined and used to facilitate the selection of a candidate material for therapeutic applications. The efficacy of the selected material as a protective coating for the colonic mucosa has been tested in a hapten-reactivated, in vivo model of inflammatory bowel disease: 7 days after reactivation of the condition, the myeloperoxidase activity of animals that had received doses of the selected azopolymer was determined to be at the same level as that of healthy animals or that of the negative control group, highlighting the therapeutic promise of this material. © 2006 Wiley Periodicals, Inc. J Biomed Mater Res, 2006
Original languageEnglish
Pages (from-to)706-715
Number of pages10
JournalJournal of Biomedical Materials Research Part A
Volume79A
Issue number3
DOIs
Publication statusPublished - Jul 2006

Keywords

  • mucoadhesion
  • azopolymers
  • colon specific drug delivery
  • inflammatory bowel disease (IBD)
  • 4,4′divinylazobenzene

Fingerprint Dive into the research topics of 'Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study'. Together they form a unique fingerprint.

Cite this